This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Start Date30 May 2025

Sponsor / Collaborator

Alliance for Clinical Trials in Oncology

[+1]

NCT06622057 / Not yet recruitingPhase 3

Phase III, Randomized, Double-blind Study of Combination Therapy With D07001-Softgel Capsules and Capecitabine vs Placebo and Capecitabine in Patients With Advanced BTC After Failed on Gemcitabine, Platin, and FOLFOX or Irinotecan Regimens

The object of this trial is to evaluate the efficacy of D07001-softgel capsules + capecitabine compared with placebo + capecitabine by overall survival (OS).
Eligible patients with advanced biliary tract cancer (BTC) will be randomized (1:1:1) to receive either 60 mg D07001-softgel, 100 mg D07001-softgel, or placebo, combine with capecitabine. Treatment will be continued until disease progression, death, withdraw consent, or completing 12 treatment cycles , whichever occurs first.

Start Date01 Apr 2025

Sponsor / Collaborator

InnoPharmax, Inc.

NCT06592664 / Not yet recruitingPhase 1/2

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV) Push of LSTA1 When Added to SoC, Versus SoC Alone in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Who Have Progressed on FOLFIRINOX (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

Start Date01 Mar 2025

Sponsor / Collaborator

Lisata Therapeutics, Inc.

100 Clinical Results associated with Gemcitabine

100 Translational Medicine associated with Gemcitabine

100 Patents (Medical) associated with Gemcitabine

19,456

Literatures (Medical) associated with Gemcitabine

01 Dec 2025·Journal of Gastrointestinal Cancer

Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)

Article

Author: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma

INTRODUCTION:

Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.

MATERIALS AND METHODS:

Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m² to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.

RESULTS:

Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.

CONCLUSIONS:

Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.

01 Mar 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Manganese nanosheets loaded with selenium and gemcitabine activate the tumor microenvironment to enhance anti-tumor immunity

Article

Author: Yuan, Wei-En ; Guan, Yuanye ; Mao, Zhenyang ; Mao, Wenwei ; Wang, Yue ; Wang, Jiayu ; Zhang, Wenkai ; Gu, Muge

Breast cancer is among the most common malignant tumors globally. Despite advances in immunotherapy and targeted therapies, chemotherapy remains the primary clinical treatment. Gemcitabine, a cytosine nucleoside analog, is widely used for various solid tumors; however, its effectiveness is often limited by drug resistance and adverse side effects. In this study, we developed a novel drug delivery system, Mn/Se-Gem, designed to target tumor cells overexpressing CD44 and facilitate the controlled release of gemcitabine. This system exploits gemcitabine's pH sensitivity and HA-mediated CD44 targeting to induce DNA damage. Simultaneously, it neutralizes the acidic tumor microenvironment and releases nano-selenium and manganese ions, which promote the excessive production of reactive oxygen species (ROS), leading to mitochondrial damage and enhanced apoptosis of cancer cells. Furthermore, Mn (II) activates the cGAS-STING pathway, increasing susceptibility to ROS-induced DNA double-strand breaks, promoting macrophage maturation, inhibiting M2 polarization, and enhancing the cytotoxic function of T lymphocytes against tumor cells. In summary, this combination of chemotherapy and immunotherapy presents a promising strategy for the treatment of breast cancer.

01 Feb 2025·BIOMATERIALS

A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance

Article

Author: Pan, Wen ; Min, Yuanzeng ; Chen, Guiyuan ; Ma, Xiaopeng ; Wang, Yangyi

Drug resistance is a significant challenge in cancer chemotherapy and is a primary factor contributing to poor recovery for cancer patients. Although drug-loaded nanoparticles have shown promise in overcoming chemotherapy resistance, they often carry a combination of drugs and require advanced design and manufacturing processes. Furthermore, they seldom approach chemotherapy-resistant tumors from an immunotherapy perspective. In this study, we developed a therapeutic nanovaccine composed solely of chemotherapy-induced resistant tumor antigens (CIRTAs) and the immune adjuvant Toll-like receptor (TLR) 7/8 agonist R848 (CIRTAs@R848). This nanovaccine does not require additional carriers and has a simple production process. It efficiently delivers antigens and immune stimulants to dendritic cells (DCs) simultaneously, promoting DCs maturation. CIRTAs@R848 demonstrated significant tumor suppression, particularly when used in combination with the immune checkpoint blockade (ICB) anti-PD-1 (αPD-1). The combined therapy increased the infiltration of T cells into the tumor while decreasing the proportion of regulatory T cells (Tregs) and modulating the tumor microenvironment, resulting in long-term immune memory. Overall, this study introduces an innovative strategy for treating chemotherapy-resistant tumors from a novel perspective, with potential applications in personalized immunotherapy and precision medicine.

1,072

News (Medical) associated with Gemcitabine

17 Dec 2024

·pipelinereview.com

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

CHICAGO, IL and FORT WORTH, TX, USA I December 17, 2024 I Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (Actuate-1801 Part 3B). A pre-specified analysis was triggered by reaching >70% death events in the GnP control arm (data cut off November 15, 2024). The analysis of interim data demonstrated treatment with elraglusib in combination with GnP resulted in statistically significant increases in 1-year survival rate (p value of 0.002) and median overall survival (p value of 0.016, hazard ratio of 0.63) versus treatment with GnP alone. The combination treatment also resulted in increased Objective Response Rates (ORR) and Disease Control Rates (DCR) in the elraglusib/GnP combination arm versus the GnP control arm. “These interim results are highly encouraging and underscore the transformative potential of elraglusib in the treatment of metastatic pancreatic cancer,” said Daniel Schmitt, President & Chief Executive Officer of Actuate. “The improvement in median and overall long-term survival, disease control rate and overall response rate compared to GnP alone, combined with elraglusib’s favorable risk-benefit profile, offers the possibility of improved outcomes for patients with limited treatment alternatives. We are excited to continue evaluating the potential of elraglusib, a novel immune-oncology GSK-3 targeted approach for mPDAC, and look forward to engaging with the FDA in 1H 2025 to share topline data and discuss next steps, including a proposed phase 3 registration trial.” Inhibition of GSK-3β may inhibit tumor growth and improve survival through several complimentary mechanisms that include enhancement of chemotherapy activity, activation of innate anti-tumor immunity and regulation of gene expression, leading to alterations in tumor metabolism and Epithelial-to-Mesenchymal Transition (EMT). Study highlights include: “Pancreatic cancer is one of the most aggressive and lethal cancers with less than 5% survival rate in the US at 5 years. We are encouraged by consistent evidence of significant clinical benefit and anti-tumor activity in the elraglusib combination arm across multiple endpoints in this study,” said Dr. Andrew Mazar, Actuate’s Scientific Co-Founder and Chief Operating Officer. “Further, the favorable risk-benefit profile observed to date may provide a treatment option for many patients with metastatic pancreatic cancer that may not tolerate more aggressive and less tolerable chemotherapy approaches.” The ongoing Actuate-1801 Part 3B study (NCT04239092) is a randomized, controlled Phase 2 trial of elraglusib with GnP versus GnP alone in first line mPDAC. The trial enrolled 286 mPDAC patients with no prior systemic treatment for metastatic disease, who were randomized 2:1 to the elraglusib treatment arm (elraglusib + GnP) or the control arm (GnP alone). Elraglusib is administered at a dose of 9.3 mg/kg by IV infusion on Day 1 of each week of a 28-day cycle. The primary endpoint is 1-year survival rate, with mOS the primary parameter for summarization of survival data at the end of the study. Secondary endpoints are DCR, ORR, PFS and AE. About Actuate Therapeutics, Inc. Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com. SOURCE : Actuate Therapeutics

Clinical ResultPhase 2Phase 3Immunotherapy

17 Dec 2024

·endpts.com

Affimed’s early lung cancer data disappoint; Indapta's $22M round

Plus, news about Akamis Bio, Tenaya Therapeutics, Reviva, Actuate Therapeutics, CG Oncology and Candel Therapeutics: Affimed shares early lung cancer data: In a Phase 1/2a trial, its bispecific innate cell engager, called AFM24, plus Roche’s Tecentriq reached a 21% overall response rate in 33 people with pretreated EGFR wild-type non-small cell lung cancer. The ORR was 24% in 17 EGFR-mutant patients. Affimed said it has selected the 720 mg dose for further development. Affimed’s shares $AFMD were down about 22% on Tuesday morning after it announced the data. — Ayisha Sharma Indapta Therapeutics gets $22.5M: The Houston and Seattle biotech raised the new round to fund clinical development of its allogeneic natural killer cell therapy. The biotech emerged with a $50 million Series A in February 2022. — Kyle LaHucik Oncolytic virus biotech has new funding and a deal in China: Akamis Bio announced that it raised new funding plus inked an out-licensing deal with Xuanzhu Biopharma for its lead candidate for up to $60 million. That figure includes private funding, the upfront for the outlicensing deal and biobucks, though CEO Howard Davis declined to disclose how much each portion is. Akamis, which rebranded from PsiOxus in 2023, is developing a gene therapy called NG-350A that is designed to target tumor cells and drive expression of CD40 agonist antibodies. The hope is that by engaging these key immune proteins, the therapy can trigger the immune system to attack the cancer. The company plans to use the funds to study the therapy in a Phase 1b rectal cancer trial. — Lei Lei Wu Tenaya’s shares slide: The company reported early results for an AAV therapy for three patients with a genetic heart condition called MYBPC3-associated hypertrophic cardiomyopathy. It pointed to biomarkers that suggested the therapy was having an initial effect, though it said “longer-term data are needed to characterize TN-201’s activity.” Tenaya said longer follow-up data as well as results from a higher dose cohort are expected next year. The company’s shares $TNYA fell 47% on Tuesday morning. — Lei Lei Wu Reviva’s long-term results for its schizophrenia drug: The Cupertino, CA-based biotech said brilaroxazine administered once daily showed sustained efficacy over one year in the open-label extension portion of a Phase 3 trial. There were no side effects with an incidence of more than 5%, but there was a 35% treatment discontinuation rate. Its stock $RVPH fell about 44% in trading on Tuesday morning. — Ayisha Sharma Actuate’s pancreatic cancer asset boosts survival: The drugmaker’s elraglusib in combination with gemcitabine and nab-paclitaxel (GnP) almost doubled the one-year survival rate versus GnP alone in a Phase 2 trial, good for a p-value of 0.002. Actuate said that 38% of treated patients were still alive at the cutoff date in November, compared with 19% of the control cohort. The company’s share price $ACTU was up 14% at market open on Tuesday. — Ayisha Sharma CG Oncology raised $238 million in its public offering, up from the $204 million it planned to bring in. — Jaimy Lee Candel ended up raising $92 million in its public offering. — Jaimy Lee

Clinical ResultPhase 3Phase 1Gene TherapyCell Therapy

17 Dec 2024

·ir.immuneering.com

Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025

- The company will provide additional data from IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer - - The company will also provide initial data from IMM-1-104 in combination with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer, as well as IMM-1-104 monotherapy in second-line pancreatic cancer - CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that it will hold a virtual Investor Event in early January 2025 to discuss data from its ongoing Phase 2a trial of IMM-1-104. Specifically, the company plans to present: Additional data from IMM-1-104 in combination with mGnP in first-line pancreatic cancer. Initial data from IMM-1-104 in combination with mFFX in first-line pancreatic cancer. Initial data from IMM-1-104 monotherapy in second-line pancreatic cancer. In addition, the company will provide initial PK, PD and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415. Details of how to access the Investor Event will be provided in due course. “We are excited to soon share additional data from our Phase 2a study of IMM-1-104 in patients with pancreatic cancer,” said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. “Pancreatic cancer patients urgently need new options that enable them to live longer and feel better. The FDA has recently granted IMM-1-104 Orphan Drug designation in pancreatic cancer, along with Fast Track designations in first and second-line pancreatic cancer, and advanced melanoma. We look forward to building on our September update with additional data from the Phase 2a study of IMM-1-104.” About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors including those harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com. Forward-Looking Statements This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: Immuneering’s plans to develop, manufacture and commercialize its product candidates; the treatment potential of IMM-1-104 and IMM-6-415, alone or in combination with other agents, including chemotherapy; and the timing for release of additional results from the Phase 2a portion of the trial for IMM-1-104 and the Phase 1 portion of the trial for IMM-6-415. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in oncology drug research and development, including target discovery, target validation, lead compound identification, and lead compound optimization; we have incurred significant losses, are not currently profitable and may never become profitable; our projected cash runway; our need for additional funding and ability to continue as a going concern; our unproven approach to therapeutic intervention; our ability to address regulatory questions and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports. These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for period ended September 30, 2024, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Media Contact: Gina Nugent gina@nugentcommunications.com Investor Contact: Laurence Watts 619-916-7620 laurence@newstreetir.com

Fast TrackPhase 2Orphan DrugPhase 1

100 Deals associated with Gemcitabine

External Link

KEGG	Wiki	ATC	Drug Bank
D02368	Gemcitabine	L01BC05	DB00441

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 3	-	RenovoRx, Inc.	01 Jun 2023
Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	AU	Panbela Therapeutics, Inc.	04 Aug 2022
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	US	RenovoRx, Inc.	12 Mar 2018
Locally Advanced Pancreatic Adenocarcinoma	Phase 3	BE	RenovoRx, Inc.	12 Mar 2018
Advanced Lung Squamous Cell Carcinoma	Phase 3	US	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	BE	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	CA	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	FR	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	DE	Sanofi	01 Mar 2010
Advanced Lung Squamous Cell Carcinoma	Phase 3	HU	Sanofi	01 Mar 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	Classical Hodgkin's Lymphoma	-	Pembrolizumab Gemcitabine Vinorelbine and Liposomal Doxorubicin (P-GVD)	jatazkeisq(gnzdsvlabg) = mqjishktrr vpndzazurp (kqcnrsvxek ) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Glofitamab with Gemcitabine and Oxaliplatin	zxpxqmbdkf(ceaheftqym) = ttsszbiyfa xoadavrhla (hgwlvoqytl, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Diffuse Large B-Cell Lymphoma	-	Rituximab with Gemcitabine and Oxaliplatin	zxpxqmbdkf(ceaheftqym) = amwmznqcob xoadavrhla (hgwlvoqytl, NA) View more	-	09 Dec 2024
ASH2024	Not Applicable	Refractory Hodgkin Lymphoma	-	Pembrolizumab Maintenance	fflrimkkst(cjebsfrlye) = ewqtgxpiat yrbhsicwmh (jifnxvvugl, 33 - 80)	-	08 Dec 2024
ASH2024	Not Applicable	Peripheral T-Cell Lymphoma	-	Lipo-MIT	zipwtyulka(llgliixhbl) = neutropenia (66.7%), leucopenia (44.4%), anaemia (33.3%) and thrombocytopenia (11.1%) vcmyqowsxj (bvhnvtafzx )	-	07 Dec 2024
ASH2024	Not Applicable	Diffuse large B-cell lymphoma recurrent	-	R-GemOx	vpyofawicc(etqkbbnvvm) = svykhtjois igqaiodmvc (igjbyzwths, 16‒29) View more	-	07 Dec 2024
NCT04989218 (ICC, CTgov)	Phase 1/2	Intrahepatic Cholangiocarcinoma	1	Tremelimumab+Gemcitabine+Cisplatin+Durvalumab	wnzpvitlrm(jncoukjpdx) = gkzbrkstyn xhgxhcgamw (snycfyjlef, wjnaoqnetm - ojixqpgbku) View more	-	05 Nov 2024
Pubmed \| Redox Biol	Not Applicable	Pancreatic Cancer	-	Gemcitabine and nab-paclitaxel only	gbalpxjwcs(uuasxhjcag) = jpuuhdqyyp lsxnanvsjj (zjodyzsekt ) View more	-	01 Nov 2024
Pubmed \| Redox Biol	Not Applicable	Pancreatic Cancer	-	Gemcitabine and nab-paclitaxel + Pharmacological ascorbate (P-AscH<sup>-</sup>)	gbalpxjwcs(uuasxhjcag) = ikdtqmdxzj lsxnanvsjj (zjodyzsekt ) View more	-	01 Nov 2024
ASTRO	Not Applicable	Muscle Invasive Bladder Carcinoma	29	Bladder Only Gemcitabine Radiotherapy	paswcmasax(tgjqziysrf) = haaqzxtmze tktqasfeuw (nlqargfodr ) View more	-	01 Oct 2024
NCT05026905 (TCOG T5221, ESMO2024) Manual	Phase 2	Pancreatic Cancer First line	50	GASL (Gemcitabine plus nab-paclitaxel and S-1/leucovorin	srcvrqvoiy(wnulbkdune) = iqbmofnjvc nbkwysecbf (damozatxco ) View more	Positive	16 Sep 2024
NCT05026905 (TCOG T5221, ESMO2024) Manual	Phase 2	Pancreatic Cancer First line	50	GAP (Gemcitabine plus nab-paclitaxel and oxaliplatin)	srcvrqvoiy(wnulbkdune) = dlekaoqaqh nbkwysecbf (damozatxco ) View more	Positive	16 Sep 2024
ESMO2024	Not Applicable	Secondary malignant neoplasm of pancreas Second line CEA \| CA 19-9	260	Gemcitabine plus nab-paclitaxel	snppjifdef(gkpwhkhbwv) = ydmsknadwx jkbathydir (kqlkbdhgsq, 5.6 - 7.1) View more	Positive	16 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis